5th Circ. Presses Illumina On Cancer Test Competition
By Matthew Perlman · September 12, 2023, 7:31 PM EDT
Illumina defended its repurchase of cancer testing outfit Grail during oral arguments at the Fifth Circuit on Tuesday, telling the panel there's no evidence the DNA sequencing company will undercut potential...
To view the full article, register now.